DEL-ZOTA
Oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, oncological, hepatological, ophthalmic, respiratory, central and/or peripheral neurological, gastrointestinal, hor...
Pending · June 25, 2024 · 98617279 ·